BACKCRC Probiotics
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 27 October 2021]
We are inviting expressions of interest (EoI) for commercializing “CRC Probiotics” technology. The innovation is developed by Professor NG Siew Chien, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 21/MED/1054).
The Technology
This invention disclosed a probiotic composition for prevention of colorectal cancer and/or adenoma, and reduction of microbial risk of colorectal cancer and/or adenoma.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
CRC Probiotics
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 27 October 2021]
We are inviting expressions of interest (EoI) for commercializing “CRC Probiotics” technology. The innovation is developed by Professor NG Siew Chien, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 21/MED/1054).
The Technology
This invention disclosed a probiotic composition for prevention of colorectal cancer and/or adenoma, and reduction of microbial risk of colorectal cancer and/or adenoma.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Therapeutics
Erika Yuen
Office of Research and Knowledge Transfer Services
NG Siew Chien
CHAN Ka Leung Francis
LIANG Qiaoyi
N/A